- Home
- CRVO vs VNRX Comparison
CRVO vs VNRX Comparison
Compare CRVO & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVO | VNRX |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 24.5M |
| IPO Year | 2011 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CRVO | VNRX |
|---|---|---|
| Price | $2.62 | $0.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $23.00 | $1.67 |
| AVG Volume (30 Days) | 327.3K | ★ 601.7K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,006,510.00 | $1,727,384.00 |
| Revenue This Year | N/A | $355.66 |
| Revenue Next Year | N/A | $849.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $2.13 | $0.13 |
| 52 Week High | $10.89 | $3.26 |
Technical Indicators
Market Signals| Indicator | CRVO | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 21.20 |
| Support Level | $2.43 | $0.19 |
| Resistance Level | $4.27 | $0.91 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 25.97 | 4.12 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.